"Why have you related PRR selling to the Dendreon result? CThis...

"Why have you related PRR selling to the Dendreon result? C
This is an insto dump

On Dendreon though "the Provenge launch isn't typical since Dendreon can't make enough to satisfy patient demand. The company long ago told investors that limited manufacturing capacity would only allow about 2,000 patients to be treated in the first 12 months of the launch."




I think that's the point & while it might of been a bit overdone & yes PRR is still miles behind DNDN what it does do is highlight how large the task ahead really is. Don't forget that this limited manafacturing capacity to meet patient demand is also after DNDN have spent hundreds of millions aimed at boosting capacity to meet this demand.

What it does do is highlight while PRR is yet to even commence Phase III trials let alone prove CVac is succesfull at the end point - that is still a very long way away & it has a need for very large capital injections at a later date for commercialisation before achieving success & becoming a player in the global pharmaceutical industry.

Investors need patience as has always been the case & why i always have & i still continue to see very little point in posters running around with "potential revenue" & throwing billion dollar price targets around at such a premature stage. It's all about baby elephant steps.



.